Real world survey of Edoxaban for non-valvular atrial fibrillation patients using a Japanese healthcare database.
- Conditions
- on-valvular atrial fibrillation
- Registration Number
- JPRN-UMIN000030744
- Lead Sponsor
- Daiichi Sankyo Co., Ltd Medical Science Department
- Brief Summary
Total of 4,144 edoxaban-treated patients were matched with same number of warfarin patients and no-anticoagulant patients. Median follow-up period for the edoxaban arm, warfarin arm, and no-anticoagulant arm was 82, 39, and 324 days. For the comparison of the edoxaban and warfarin arms, and edoxaban and no-anticoagulant arm, no difference was found in the incidence of stroke/systemic embolism. The findings are limited by the short mean follow-up period in both treatment arms.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 4414
Not provided
1, Patients who underwent total knee replacement surgery 2, Patients who underwent total hip replacement surgery 3, Patients who underwent hip fracture surgery 4, Patients who have an artificial heart valves 5, Patients who have been given the diagnosis of rheumatic mitral valve diseases 6, Patients who have stroke, systemic embolism events, and/or bleeding events
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1,stroke 2,systemic embolism 3,bleeding
- Secondary Outcome Measures
Name Time Method